Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.51 |
| ▸ | FABP7 | O15540 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23185453 | 0.89 | EPHX2 (0.47) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL23483022 | 0.87 | EPHX2 (0.43) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL19631129 | 0.87 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL7037298 | 0.87 | KMT2A (0.54) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL20623130 | 0.87 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL17753728 | 0.87 | KMT2A (0.54) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL14543452 | 0.87 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL20445462 | 0.87 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL20334407 | 0.86 | KMT2A (0.41) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL23667890 | 0.85 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 646 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239786-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER | YALE UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20240239786-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER | YALE UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-12030834-B2 | Methods of synthesizing 4-valyloxybutyric acid | XWPharma Ltd. (KY) | 2024-07-09 | — | — | US | disclosed |
| US-20240216361-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B V (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-06-27 | — | — | US | disclosed |
| EP-3790886-B1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-27 | — | — | US | disclosed |
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | SAREPTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20080118464-A1 | For diagnosis, genetic engineering; post-translation modification | AMBRX, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20070281934-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281934-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070244128-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| US-7169899-B1 | Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents | TRANZYME PHARMA INC. (CA) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | KMT2A 3688/4885FABP5 786/4885FABP7 1281/4885 |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | KMT2A 2012/4885FABP5 2241/4885FABP7 2593/4885 |
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | HTT, UPF1, TARDBP | KMT2A 1123/4885FABP5 1471/4885FABP7 505/4885 |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | KMT2A 4230/4885FABP5 79/4885FABP7 362/4885 |
| US-20080118464-A1 | For diagnosis, genetic engineering; post-translation modification | PTMS, ANPEP, AADAT | KMT2A 806/4885FABP5 1181/4885FABP7 895/4885 |
| US-20070244128-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | KMT2A 4230/4885FABP5 79/4885FABP7 362/4885 |
| US-12030834-B2 | Methods of synthesizing 4-valyloxybutyric acid | GABBR1, GABBR2, GABRB3 | KMT2A 2039/4885FABP5 464/4885FABP7 479/4885 |
| US-20240216361-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | KMT2A 2043/4885FABP5 850/4885FABP7 1152/4885 |
| US-20070281934-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC2 | KMT2A 63/4885FABP5 2142/4885FABP7 1608/4885 |
| US-20240239786-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER | BRCA1, RAD51, PARP3 | KMT2A 1743/4885FABP5 3960/4885FABP7 4854/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | KMT2A 4230/4885FABP5 79/4885FABP7 362/4885 |
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | API5, XIAP, BIRC5 | KMT2A 4599/4885FABP5 630/4885FABP7 871/4885 |
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | COL2A1, COL14A1, COL1A1 | KMT2A 4353/4885FABP5 1484/4885FABP7 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.